Prasinezumab for early Parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests a new medication called prasinezumab, given through a vein (IV), to see if it can slow the progression of early-stage Parkinson's disease. It is for people who are on only one Parkinson's medication and have not yet developed motor complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Weigh between 88 and 242 pounds and have a body mass index between 18 and 34.
- Have been diagnosed with early-stage Parkinson's disease by a doctor using standard criteria.
- Be taking only one Parkinson's medication (monotherapy) at the time of the study.
- Have no motor complications from your medication (like uncontrolled movements or wearing-off).
- Be in the early stages of Parkinson's (Hoehn and Yahr Stage 1 or 2) when off medication.
- Agree to use contraception if needed, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an experimental drug called prasinezumab can help prevent memory and thinking problems in people with Parkinson's disease who carry a specific GBA gene change. It aims to slow down cognitive decline and improve quality of life.
This trial tests an experimental drug called RO7568282 to see if it is safe and can help with early Parkinson's disease symptoms. It is for people who have been taking a stable dose of levodopa alone for at least two months.
This study tests an investigational drug called MT101-5 for people with early Parkinson's disease. The goal is to see if it is safe and can help slow the progression of symptoms.
This trial tests a new experimental drug called ALN-SNCA, given as an injection into the spinal fluid, for people with early Parkinson's disease. The goal is to see if it is safe and well-tolerated.
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.